Duopharma Biotech

Duopharma Biotech portfolio of generic drugs serve therapeutic classes, manufactured and distributed to domestic and international markets.

Duopharma Biotech Berhad officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik.

Kuala Lumpur November 27, 2018 – High quality, internationally proven biosimilar diabetic therapy that is cost effective can effectively substitute ‘branded’ innovator drugs in reducing the burden on public health and paying patients to manage the cost of treating diabetes in Malaysia, which has the highest number of diabetics in the Asean region.

Articles & Insights Back to news & Media

Dato’ Adnan Hisham Bin Pawanteh serves as an independent, non-executive director, appointed to the board on 22 May 2025.

Ibrahim Hussin Salleh serves as Chief Legal Officer and Group Company Secretary, appointed on 28 December 2017.

Krisnakumara-Reddi A/L Kesava-Reddi holds the position of Chief Manufacturing & Sustainability Officer, appointed on 6 October 2022.

Encik Muhammad Shukri Bin Ismail Non-Independent Non-Executive Alternate Director to Encik Mohamad Idros Bin Mosin Date of Appointmentto the Board22...

Duopharma Biotech promotes healthcare equity in Malaysia through ESG-focused business strategies and innovation.

Duopharma Biotech operates three R&D and manufacturing facilities in the Klang Valley, Malaysia.

Duopharma Biotech is committed to halal pharmaceutical production, holistic manufacturing and halal consumer healthcare through certification and collaboration.

Duopharma Biotech specializes in research, development, manufacturing, commercialization, and marketing of healthcare solutions.